Skip to main content

Table 5 Prognostic value of clinicopathological factors and TRPM7 methylation using univariate and multivariate Cox regression analysis

From: Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancers

Characteristics

Univariate

Multivariate

HRa (95% CI)

P

HRa (95% CI)

P

TRPM7 methylation

0.50 (0.25–1.01)

0.06

0.50 (0.23–1.08)

0.07

Ageb

1.10 (0.86–1.40)

0.45

1.15 (0.88–1.52)

0.31

WHO gradec

1.12 (0.56–2.23)

0.75

/

 

Molecular subtyped

1.14 (0.86–1.53)

0.36

1.15 (0.81–1.63)

0.45

LNMe

1.28 (0.66–2.48)

0.46

0.91 (0.31–2.65)

0.86

Endocrine therapy

0.63 (0.33–1.18)

0.15

0.69 (0.36–1.32)

0.26

Radiotherapy

1.32 (0.69–2.51)

0.39

1.00 (0.34–2.97)

0.99

Chemotherapy

1.48 (0.53–4.19)

0.45

1.46 (0.46–4.64)

0.52

Relapse

83.01 (35.58–212.77)

0.001

/

 
  1. aHR: hazard ratio with 95% confidence interval (CI); bAge (per 10 years); cWHO grade (I, II, III and IV); dMolecular subtypes (Luminal A, Luminal B, Her2 positive and Basal like); eLymph node metastasis